Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-20T00:58:36.065Z Has data issue: false hasContentIssue false
  • English
  • Français

Understanding recent increases in chronic disease treatment rates: more disease or more detection?

Published online by Cambridge University Press:  01 October 2010

David H. Howard ,
Kenneth E. Thorpe  and
Susan H. Busch
David H. Howard*
Affiliation:
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
Kenneth E. Thorpe
Affiliation:
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
Susan H. Busch
Affiliation:
Division of Health Policy and Administration, Yale School of Public Health, Yale University, New Haven, CT, USA
*
*Correspondence to: David Howard, Department of Health Policy and Management, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA. E-mail: david.howard@emory.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

The proportion of the population treated for major medical conditions, including diabetes, cancer and mental illness, increased rapidly during the 1990s. We document the magnitude of these increases and use a model of prevalence to identify three potential causes: increased clinical incidence of disease, longer survival times among persons with chronic illnesses and increased detection. We present a series of analyses to evaluate the contribution of each factor. We find that increases in obesity explain a large proportion of the increase in treatment rates for conditions closely linked to obesity (e.g. diabetes). We provide some evidence that increases in treated prevalence unexplained by changes in the underlying clinical incidence of disease are driven by increased detection and treatment of patients with ‘subclinical’ illness.

Type
Articles
Information
Health Economics, Policy and Law , Volume 5 , Issue 4 , October 2010 , pp. 411 - 435
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F.Feuer, E. J., For the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators (2005), Effect of screening and adjuvant therapy on mortality from breast cancer, New England Journal of Medicine, 353: 1784–1792.Google Scholar
Burt, V. L., Cutler, J. A., Higgins, M., Horan, M. J., Labarthe, D., Whelton, P., Brown, C.Roccella, E. J. (1995), ‘Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population data from the Health Examination Surveys, 1960 to 1991’, Hypertension, 26(1): 60–69.CrossRefGoogle ScholarPubMed
Cawley, J., Burkhauser, R. V. (2006), Beyond BMI: The Value of More Accurate Measures of Fatness and Obesity in Social Science Research. NBER Working Paper 12291.Google Scholar
Cohen, J. W.Krauss, N. A. (2003), ‘Spending and service use among people with the fifteen most costly medical conditions, 1997’, Health Affairs, 22(2): 129–138.Google Scholar
Conrad, P. (2005), ‘The shifting engines of medicalization’, Journal of Health and Social Behavior, 46: 3–14.Google Scholar
Critser, G. (2005), Generation Rx. How Prescription Drugs Are Altering American Lives, New York: Houghton Mifflin Company.Google Scholar
Cutler, D. M.Meara, E. (2000), ‘The technology of birth: is it worth it?’, Frontiers in Health Policy Research, Article 3. http://www.bepress.com/Fhep/3/3/Google Scholar
Cutler, D. M., McClellan, M., Newhouse, J. P.Remler, D. (1998), ‘Are medical prices falling?’, Quarterly Journal of Economics, 113(4): 991–1024.Google Scholar
Etzioni, R., Berry, K. M., Legler, J. M.Shaw, P. (2002), ‘Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991–1998’, Urology, 59: 251–255.Google Scholar
Fairlie, R. W. (2005), ‘An extension of the Blinder-Oaxaca decomposition technique to logit and probit models’, Journal of the Economic and Social Measurement, 3: 305–316.Google Scholar
Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E.Colditz, G. A. (2001), ‘Impact of overweight on the risk of developing common chronic diseases during a ten-year period’, Archives of Internal Medicine, 161(13): 1581–1586.Google Scholar
Flegal, K. M., Carroll, M. D., Ogden, C. L.Johnson, C. L. (2002), ‘Prevalence and trends in obesity among US adults, 1999–2000’, Journal of the American Medical Association, 288: 1723–1727.Google Scholar
Grossman, G. M.Shapiro, C. (1984), ‘Informative advertising with differentiated products’, Review of Economic Studies, 5(1): 63–81.Google Scholar
Gregg, E. W., Cheng, Y. J., Cadwell, B. L., et al. (2005), ‘Secular trends in cardiovascular disease risk factors according to body mass index in US adults’, Journal of the American Medical Association, 293(15): 1868–1874.Google Scholar
Herndon, M. B., Schwartz, L. M., Woloshin, S.Welch, H. G. (2007), ‘Implications of expanding disease definitions: the case of osteoporosis’, Health Affairs, 26(6): 1702–1711.Google Scholar
Iizuka, T. (2004), ‘What explains the use of direct-to-consumer advertising of prescription drugs?’, The Journal of Industrial Economics, LII(3): 349–379.CrossRefGoogle Scholar
Kaplan, R. M.Ong, M. (2007), ‘Rationale and public health implications of changing CHD risk factor definitions’, Annual Review of Public Health, 28: 321–344.CrossRefGoogle Scholar
Klawiter, M. (2005), ‘The Biopolitics of Risk and the Configuration of Users: Clinical Trials, Pharmaceutical Technologies, and the New Consumption-Junction’, in S. Frickel and K. Moore (eds), The New Political Sociology of Science: Institutions, Networks, and Power, Madison, WI: University of Wisconsin Press.Google Scholar
Legorreta, A. P., Silber, J. H., Costantino, G. N., Kobylinski, R. W.Zatz, S. L. (1993), ‘Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy’, Journal of the American Medical Association, 270(12): 1429–1432.Google Scholar
Moynihan, R.Cassels, A. (2005), Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All into Patients, NY: Nation Books.Google Scholar
Must, A., Spadano, J., Coakley, E. H., Field, A. E., Colditz, G.Dietz, W. H. (1999), ‘The disease burden associated with overweight and obesity’, Journal of the American Medical Association, 282(16): 1523–1529.Google Scholar
National Center for Health Statistics 2006. Health, United States, 2006, with Chartbook on Trends in the Health of Americans. Hyattsville, MD.Google Scholar
Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Epstein, A. M.Frank, R. G. (2003), ‘Demand Effects of Recent Changes in Prescription Drug Promotion’, in Frontiers in Health Policy Research, Cambridge and London: MIT Press for the National Bureau of Economic Research 6: 1–26.Google Scholar
Schenthal, J. E. (1960), ‘Multiphasic screening of the well patient’, Journal of the American Medical Association, 172(1): 51–54.Google Scholar
Schwartz, L. M.Woloshin, S. (1999), ‘Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988–1994’, Effective Clinical Practice, 2: 76–85.Google Scholar
Thorpe, K. E., Florence, C. S., Howard, D. H.Joski, P. (2005), ‘The impact of rising disease prevalence on private health insurance spending’, Health Affairs, 5: w317–w325.Google Scholar